Drug intelligence / Profile preview

AKB-9778 + ranibizumab

Development stage: Unknown
Lead developer: Aadi Bioscience
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Subcutaneous, Intravitreal

Overview

AKB-9778 + ranibizumab is a combination therapy for diabetic macular edema (DME). AKB-9778 is a small-molecule vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibitor that activates the Tie2 receptor. By inhibiting VE-PTP, AKB-9778 promotes vascular stabilization and protects against vascular leak and pathologic angiogenesis. Ranibizumab is an anti-VEGF agent administered intravitreally. The combination has shown enhanced efficacy in reducing macular edema compared to either agent alone, with a significant reduction in central subfield thickness (CST) in clinical trials.

Targets

PTPRB (Vascular endothelial-protein tyrosine phosphatase)VEGFA (Vascular endothelial growth factor A)TEK (Tie2)

Beyond the preview

Go deeper on AKB-9778 + ranibizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AKB-9778 + ranibizumab.

Explore the full profile